Dalpiciclib with hormone therapy before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new combination of two medications given before surgery for stage II-III hormone-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes, possibly making surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer that is hormone receptor-positive (meaning it grows in response to hormones) and HER2-negative.
- Your breast cancer is stage II or III and has not spread to other parts of the body.
- You have not had any previous treatment for this breast cancer, such as chemotherapy, radiation, or hormone therapy.
- You are either postmenopausal or have had your ovaries removed.
- You are generally in good health, able to perform daily activities, and can swallow pills.
- You are willing to have tumor biopsies and follow the study protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This study tests a new combination of treatments given before surgery for breast cancer that is hormone-receptor positive and HER2-low. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes. You might be eligible if you have not yet had any treatment for breast cancer.
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This trial tests a combination of two drugs, dalpiciclib and letrozole, as maintenance therapy after first-line chemotherapy for HR-positive, HER2-negative metastatic breast cancer. The goal is to see if this combination helps keep the cancer from growing.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.